 |
Доповіді НАН України. – 2008. – N 10. – С. 182–185.
Комбінована дія паклітакселю та селективного інгібітора NFκB дегідроксиметилепоксиквіноміцину на клітини фолікулярного раку щитовидної залози
В.М. Пушкарьов, Д.В. Старенький, В.М. Гончарук, С. Ямашита, В.О. Саєнко, М.Д. Тронько
Abstract
A novel nuclear factor kappa B (NFκВ) inhibitor,
dehydroxymethylepoxyquinomicin, is found to enhance the cytotoxic effect of
an anticancer drug paclitaxel in the FRO cell line derived from
nondifferentiated thyroid carcinoma of the follicular origin. A strong
activation of caspases and PARP cleavage, as well as the decreased levels of
small proteins-suppressors of apoptosis, are observed when cells are treated
with a combination of both drugs. Of note are the singular paclitaxel treatment
induced NFκВ activation and the NFκВ-dependent phosphorylation
of cRaf-1, an upstream kinase of ERK1/2 which is a key member of the
mitogen-activated signaling cascade that may comprise an additional
NFκВ-induced antiapoptotic pathway. Thus, the combination of
paclitaxel and NFκВ inhibitor is a promising pharmacological
strategy for further preclinical trials aimed at the development of new
therapeutic approaches to the treatment of nondifferentiated and anaplastic
thyroid cancer.
Повний текст статі в pdf-форматі
| Назад до номера | Вибір номера | Головна сторінка журналу | Головна сторінка Порталу |